Oral corticosteroids

Preclinical

Sanofi

Oral corticosteroids is one of 6 therapeutic programs targeting Dermatitis, Atopic. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Dermatitis, AtopicEnrolling by invitation

Dermatitis, AtopicPreclinical

Enrolling by invitation

Competition

Competitive Landscape

9 competitors in Dermatitis, Atopic

#DrugCompanyPhaseTrials

Amlitelimab

Sanofi

Phase 3

3 2

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

2 3

Topical Corticosteroids

Sanofi

Phase 3

2 4

JNJ-95597528

Johnson & Johnson

Phase 2

1 5

JNJ-95475939

Johnson & Johnson

Phase 2

1 6

Oral corticosteroids

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dermatitis, Atopic1 trial

A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants of Previous Amlitelimab Clinical Trials in Moderate to Severe Atopic Dermatitis.

Enrolling by invitation· Sanofi logo

Sanofi·Preclinical·NCT05492578·1,663 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oral corticosteroids. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Oral corticosteroids. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Sanofi

Oral corticosteroids

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Dermatitis, Atopic1 trial

References

Drug Info

Quick Facts

Related News